ranbezolid and Bacterial-Infections

ranbezolid has been researched along with Bacterial-Infections* in 2 studies

Other Studies

2 other study(ies) available for ranbezolid and Bacterial-Infections

Article	Year
Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis. International journal of antimicrobial agents, 2013, Volume: 41, Issue:1 This study reports the anti-anaerobic properties of ranbezolid, a new investigational oxazolidinone. A time-kill kinetics study against anaerobes showed that ranbezolid was superior to linezolid and killed the anaerobic pathogens at 4-8h, except for Bacteroides fragilis where killing was observed at 24h. In addition, the time-kill kinetics study showed a concentration-dependent bactericidal potential of ranbezolid against anaerobes. Ranbezolid showed 5.39log(10) reduction and linezolid showed 1.15log(10) reduction in murine disk implant infection with B. fragilis ATCC 25285. Ranbezolid was very potent and showed fast protein synthesis inhibition against B. fragilis, a Gram-negative anaerobe. In addition, non-specific cell wall synthesis inhibition was also observed with ranbezolid. The potent and fast protein synthesis inhibition along with an additional mode of action of cell wall synthesis inhibition could be responsible for the cidal effect of ranbezolid against Gram-negative anaerobes. Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Cell Wall; Foreign Bodies; Furans; Mice; Microbial Sensitivity Tests; Microbial Viability; Oxazoles; Protein Biosynthesis; Time Factors; Treatment Outcome	2013
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:3 The activity of ranbezolid (RBX 7644), a new oxazolidinone, against 306 anaerobes was compared with those of 11 other agents. The MICs at which 50% of the isolates tested are inhibited and those at which 90% of the isolates tested are inhibited (in micrograms per milliliter) were as follows: ranbezolid, 0.03 and 0.5; linezolid, 2 and 4; vancomycin, >16 and >16; teicoplanin, 1 and >16; quinupristin-dalfopristin, 1 and >8; amoxicillin-clavulanate, 0.5 and 2; imipenem, 0.125 and 1; clindamycin, 0.25 and 8; metronidazole, 1 and 4; gatifloxacin, 0.5 and 4; and moxifloxacin, 0.5 and 2, respectively. Ranbezolid had very good in vitro activity against both gram-negative and -positive anaerobes. Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Culture Media; Furans; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Humans; Kinetics; Microbial Sensitivity Tests; Oxazoles	2003

Article

Year

Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis.

International journal of antimicrobial agents, 2013, Volume: 41, Issue:1

This study reports the anti-anaerobic properties of ranbezolid, a new investigational oxazolidinone. A time-kill kinetics study against anaerobes showed that ranbezolid was superior to linezolid and killed the anaerobic pathogens at 4-8h, except for Bacteroides fragilis where killing was observed at 24h. In addition, the time-kill kinetics study showed a concentration-dependent bactericidal potential of ranbezolid against anaerobes. Ranbezolid showed 5.39log(10) reduction and linezolid showed 1.15log(10) reduction in murine disk implant infection with B. fragilis ATCC 25285. Ranbezolid was very potent and showed fast protein synthesis inhibition against B. fragilis, a Gram-negative anaerobe. In addition, non-specific cell wall synthesis inhibition was also observed with ranbezolid. The potent and fast protein synthesis inhibition along with an additional mode of action of cell wall synthesis inhibition could be responsible for the cidal effect of ranbezolid against Gram-negative anaerobes.

Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Cell Wall; Foreign Bodies; Furans; Mice; Microbial Sensitivity Tests; Microbial Viability; Oxazoles; Protein Biosynthesis; Time Factors; Treatment Outcome

2013

Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.

Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:3

The activity of ranbezolid (RBX 7644), a new oxazolidinone, against 306 anaerobes was compared with those of 11 other agents. The MICs at which 50% of the isolates tested are inhibited and those at which 90% of the isolates tested are inhibited (in micrograms per milliliter) were as follows: ranbezolid, 0.03 and 0.5; linezolid, 2 and 4; vancomycin, >16 and >16; teicoplanin, 1 and >16; quinupristin-dalfopristin, 1 and >8; amoxicillin-clavulanate, 0.5 and 2; imipenem, 0.125 and 1; clindamycin, 0.25 and 8; metronidazole, 1 and 4; gatifloxacin, 0.5 and 4; and moxifloxacin, 0.5 and 2, respectively. Ranbezolid had very good in vitro activity against both gram-negative and -positive anaerobes.

Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Culture Media; Furans; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Humans; Kinetics; Microbial Sensitivity Tests; Oxazoles

2003